Skip to main content
Premium Trial:

Request an Annual Quote

Opko Health Raises $31M in Private Stock Placements


Opko Health announced this week that it has raised $31 million through private stock placements with seven investment groups.

The money comes at a key time for Opko, which earlier this year said that a $20 million stock purchase by a group controlled by the company's chairman and CEO would only give it enough resources to continue operations into early 2010 (see RNAi News, 3/19/2009).

Under the terms of the most recent investment deals, Opko will issue 31 million shares of its common stock at $1 per share. During morning trading on the Nasdaq today, shares of the company were selling for $1.20 apiece.

Investors participating in the transactions include Vector Group, Chung Chia Company, Grandtime Associates, Gold Sino Assets, Oracle Partners, Oracle Institutional Partners, and Nora Real Estate.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.